Veradermics, Incorporated Common Stock Overview
Industry: Pharmaceutical Preparations
Sector: Healthcare
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss. Veradermics aims to develop a focused portfolio of aesthetic dermatology product candidates targeting high-prevalence dermatologic conditions, with potential selective development of medical dermatology product candidates. Its lead program, VDPHL01, is being developed as an oral, non-hormonal treatment for men and women with pattern hair loss, to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform pattern hair loss treatment. VDPHL01 is an oral, extended-release proprietary formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidils impact on hair restoration while minimizing the risk of cardiac activity. Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss. Veradermics aims to develop a focused portfolio of aesthetic dermatology product candidates targeting high-prevalence dermatologic conditions, wi Read More
Newly listed company coverage
Verified company profile, price history, and SEC registration source are available.
10-Q/10-K financial data, or the foreign-issuer equivalent, is not available yet.
Review the SEC registration filingReported Results
No latest earnings report cached yet
Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.
Recent News
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Annual 10-K/20-F financial statement data is not available yet.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.